Search
bapineuzumab
Indications:
- none
Contraindications:
- treatment of Alzheimer's disease
Dosage:
- intravenous administration
Mechanism of action:
- monoclonal antibody against beta-amyloid
Clinical trials:
- in 2 clinical trials, bapineuzumab failed to improve cognitive function in patients with mild to moderate Alzheimer's disease
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
pharmaceutical monoclonal antibody
neurologic agent
References
- Reuter August 7, 2012
Pfizer, J&J scrap Alzheimer's studies as drug fails
http://www.reuters.com/article/2012/08/07/us-pfizer-alzheimers-idUSBRE8751F120120807
- Associated press, August 6, 2012
J&J, Pfizer to drop intravenous Alzheimer's drug
http://online.wsj.com/article/APffd2cec117944e4c9c045ca6f21513f7.html
- Salloway S et al
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate
Alzheimer's Disease.
N Engl J Med 2014; 370:322-333. January 23, 2014
PMID: 24450891
http://www.nejm.org/doi/full/10.1056/NEJMoa1304839